Apr 16, 2024 · Winrevair (sotatercept) is an injectable activin signaling inhibitor that can be self-administered subcutaneously and may be used to treat adults with pulmonary arterial hypertension (PAH, WHO Group 1).

Mar 26, 2024 · WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH.

Learn more about WINREVAIR™ (sotatercept-csrk), review the Patient Information and Instructions for Use (1-vial kit, 2-vial kit).

Apr 30, 2024 · Winrevair (sotatercept-csrk) is commonly used to treat pulmonary arterial hypertension (PAH). PAH is high blood pressure in the blood vessels (pulmonary arteries) that go to your lungs from your...

WINREVAIRTM is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO...

Nov 1, 2024 · WINREVAIR is an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.

WINREVAIR™ is a prescription medicine used to treat adults with pulmonary arterial hypertension (PAH). PAH is a type of high blood pressure in the arteries of your lungs.

Sotatercept, sold under the brand name Winrevair is a medication used for the treatment of pulmonary arterial hypertension. [6] It is an activin signaling inhibitor, [6] based on the extracellular domain of the activin type 2 receptor expressed as a recombinant fusion protein with immunoglobulin Fc domain (ACTRIIA-Fc). [9]

WINREVAIR is an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, WHO Group 1) to increase exercise capacity, improve WHO functional class (FC) and reduce the risk of clinical worsening events. (1) ------------------------DOSAGE AND ADMINISTRATION-----------------------

WINREVAIR is an activin signaling inhibitor indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. Erythrocytosis: WINREVAIR may cause increases in hemoglobin (Hgb).